Safety attrition of drugs during preclinical development as well as in late-stage clinical trials continues to be a challenge for the pharmaceutical industry for patient welfare and financial reasons. Hepatic, cardiac, and nephrotoxicity remain the main reasons for compound termination. In recent years, efforts have been made to identify such liabilities earlier in the drug development process, through utilization of in silico and cytotoxicity models. Several publications have aimed to predict specific organ toxicities. For example, two large-scale evaluations of hepatotoxic compounds have been conducted. In contrast, only small cardiotoxic and nephrotoxic compound sets have been evaluated. Here, we investigated the utility of hepatic-, cardiac-, and kidney-derived cell lines to (1) accurately predict cytotoxicity and (2) to accurately predict specific organ toxicities. We tested 273 hepatotoxic, 191 cardiotoxic, and 85 nephrotoxic compounds in HepG2 (hepatocellular carcinoma), H9c2 (embryonic myocardium), and NRK-52E (kidney proximal tubule) cells for their cytotoxicity. We found that the majority of compounds, regardless of their designated organ toxicities, had similar effects in all three cell lines. Only approximately 5% of compounds showed differential toxicity responses in the cell lines with no obvious correlation to the known in vivo organ toxicity. Our results suggest that from a general screening perspective, different cell lines have relatively equal value in assessing general cytotoxicity and that specific organ toxicity cannot be accurately predicted using such a simple approach. Select organ toxicity potentially results from compound accumulation in a particular tissue, cell types within organs, metabolism, and off-target effects. Our analysis, however, demonstrates that the prediction can be improved significantly when human C max values are incorporated.
Attrition in drug development remains high, with toxicity being the leading cause at all stages of the drug development process. This causes a problem for the pharmaceutical industry for patient welfare and monetary reasons. In a recent review, Allen et al. (2010) estimated that a 10% improvement in predicting failure before the initiation of expensive and timeconsuming clinical trials could save upwards of $100 million in the costs associated with drug development. Efforts have been made, and continue to be made, to position safety assessment earlier and earlier in the drug development process.
Testing for potential liabilities has included the areas of drug metabolism and pharmacokinetic (PK) characteristics, various safety endpoints including predevelopment safety pharmacology, general toxicology, and genetic toxicology, and interrogation of counterscreen data to identify off-target affinities (i.e., receptors, ion channels, transporters, kinases, etc.) that pose a concern (Bass et al., 2009) .
Among the many important areas of concern are the potential for toxicities of the major organ systems. Hepatotoxicity and cardiotoxicity remain the two major reasons for drug attrition (Schuster et al., 2005) , as well as kidney toxicity within Pfizer's own portfolio. Considerable progress has been toward prediction of organ-specific toxicity, particularly for hepatotoxicity (O'Brien et al., 2006; O'Connell and Watkins, 2010; Xu et al., 2008) , with more limited efforts toward the prediction of cardiotoxicity (e.g., QT prolongation) and other organ-specific toxicities (Fermini and Fossa, 2003; Frid and Matthews, 2010; Inoue et al., 2007; Zhang et al., 2007) .
In the future, toxicology will move to a predominantly predictive science focused upon broad inclusions of targetspecific, mechanism-based biological observations from a predominantly observational science at the level of disease-specific models (Andersen et al., 2010; Berg et al., 2011) . This implies that the traditional in vivo-centered toxicity practice will be shifted more toward in vitro cell-based studies. Consequently, there has been increased effort in toxicology to develop and validate new approaches to risk assessment Marchant et al., 2009; McKim, 2010; Nadanaciva et al., 2010; Xia et al., 2008) .
One of the approaches has been measuring cytotoxic drug effects on cultured cells using either single or multiple endpoints using plate-based or high-content screening assays. For example, Xia et al. (2008) tested > 1000 compounds previously tested in one or more traditional toxicologic assays by high-throughput screening (HTS) in 13 human and rodent cell types derived from six common targets of xenobiotic toxicity (liver, blood, kidney, nerve, lung, and skin). The authors found that some compounds were cytotoxic to all cell types at similar concentrations, whereas others exhibited species-or cell type-specific cytotoxicity.
Another example by O'Brien et al. (2006) used high-content screening to predict a drug's potential to cause hepatotoxicity in HepG2 cells. Of the eight parameters utilized in this assay, cell number was found to be the most sensitive predictor of cytotoxicity. The predictivity of the assay further increased when compounds were tested at 30 times the human maximal efficacious serum concentration (C eff ) reported. The advantage of such cell-based assay approaches is that they could potentially provide mechanistic information in addition to having high-throughput capability.
To our knowledge, no such comprehensive compound (drug) set has been evaluated for the prediction of either cardiac or nephrotoxicity.
Here, we expanded on such studies by performing a largescale evaluation of 273 hepatotoxic compounds, 191 cardiotoxic compounds, 85 nephrotoxic compounds, and 72 compounds with no reported organ toxicity. These compounds were either commercially available drugs or Pfizer internal compounds. We tested these compounds for their cytotoxicity potential in HepG2 cells (hepatocellular carcinoma), H9c2 cells (embryonic myocardium), and NRK-52E (kidney proximal tubule) cells. We first investigated their utility for predicting organ toxicity and whether using a target organ-related cell line could accurately predict organ toxicity, and secondly, whether C max -considered analysis would increase such prediction. Our results suggest that three organ-specific cell lines have relatively equal value in assessing general cytotoxicity and that organ toxicity cannot be accurately predicted using such a simple approach. Such toxicity potentially results from compound accumulation in a particular tissue, metabolism, and off-target effects. However, our analysis demonstrates that the prediction can be significantly improved when human C max values are incorporated. In fact, projection against 303 and 1003 the human C max value increased the predictivity even further.
MATERIALS AND METHODS

Materials
All tissue culture reagents were purchased from either Sigma (St Louis, MO) or Invitrogen (Carlsbad, CA). The CellTiter-Glo kit was purchased from Promega (Madison, WI). The 384-well microplates (Corning 3712) for the luminescence assays were purchased from Corning (Corning, NY). The 384-well microplates (Matrix 4312) for compound spotting were purchased from Thermo Fisher Scientific (Waltham, MA). Compounds were purchased from Sigma and Toronto Research Chemicals (Toronto, Canada) or were synthesized internally at Pfizer.
Methods
Tissue culture. H9c2, NRK-52E, and HepG2 cells were purchased from the American Type Culture Collection (Manassas, VA) and cultured in Dulbecco's Modified Eagle's Medium (Invitrogen 11995-065) containing 25mM glucose, 1mM sodium pyruvate, supplemented with 5mM N-2-hydroxyethyl piperazine-N#-2-ethanesulfonic acid, 10% fetal bovine serum, and penicillin-streptomycin (50 unit/ml and 50 lg/ml as final concentrations, respectively). Cells were cultured at 37°C, 5% CO 2 , and 95% humidity. H9c2, NRK-52E, and HepG2 cells were harvested in the exponential growth phase for the experiments and passaged every 3 days up to a maximum passage of 15. Cells were maintained on 175-cm 2 flasks and seeded onto 384-well plates for individual experiments with a density of 600 cells per well for HepG2 and NRK-52E and 1000 cells per well for H9c2.
Compounds. Four hundred ninety-seven compounds were utilized in this study, which included 305 commercially available compounds as well as 192 Pfizer proprietary compounds. Of the 497 compounds, 273 were designated as primarily hepatotoxic, 191 as primarily cardiotoxic, 85 as primarily nephrotoxic, and 72 as nontoxic. This classification of toxic and nontoxic was based on clinical data of hepatotoxicity (Kaplowitz, 2005; Lee, 2003; Stricker, 1992; Zimmerman, 1999) and for cardiac and nephrotoxicity on automated queries to retrieve public information on drug-toxicity relationships, which was manually curated to our specifications.
Therapeutic exposure levels (C max ) were obtained from a combination of literature searches and commercially available databases (PubMed, Physicians' Desk Reference, Prous, and Pharmapendium). The therapeutically active average plasma maximum concentration (C max ) values were collated upon single-dose administration at commonly recommended therapeutic doses. In cases where multiple recommended doses were available, the average total C max corresponding to a single administration at the median dose was used. A compound was declared safe if the above-mentioned tools did not indicate human organ toxicity. For Pfizer internal compounds, toxicity was found preclinically below the projected human efficacious plasma drug concentration.
All compounds were reconstituted in 100% dimethyl sulfoxide (DMSO) as 30mM stock solutions. All compounds were soluble in DMSO at 30mM. Compound plates were stored at room temperature in inert nitrogen boxes for a maximum of 3 months. Test compounds were prepared using 11 doses in a twofold dilution scheme ranging from 30 to 0.03mM. One microliter of each dilution was spotted onto an assay plate for use in the assay within 24 h. One microliter of 1003 compound spotted in compound plates was mixed with 99 ll of high glucose-containing growth media to obtain 13 compound dilutions for the immediate treatment of cells. DMSO titrations were performed at 5, 4, 3, 2, 1, 0.5, and 0.1%. DMSO concentrations 2% did not affect viability (data not shown). The final concentration of DMSO in the culture media was 1%. The final drug concentrations were 300-0.3lM. Each compound was tested in triplicate within a run, and three independent runs (different days) were performed for each of the three cell lines.
Cytotoxicity (ATP depletion) assay. ATP content was measured as follows: 72 h after compound treatment, cells in 30 ll media were cooled to room temperature and mixed with an equal volume of assay reagents (CellTiterGlo, Promega). Cells and reagents were mixed by shaking the plates on a shaker (VWR, Microplate shaker) at 280 revolutions per minute for 5 min. After an additional 15 min of incubation at room temperature, the plates were measured for their luminescent light intensity using an EnVision reader (2103 Multilabel PerkinElmer).
Data analysis. Pfizer internal data analysis software (SIGHTS), GraphPad Prism, and Microsoft Excel were used for the data calculation and analysis. Raw data were first analyzed using SIGHTS for assay quality evaluation. Only plates that generated Z# value (Sui and Wu, 2007 ) > 0.5 were used for The half maximal inhibitory concentration (IC 50 ) calculation. IC 50 values were calculated using a nonlinear regression curve fit with four parameters. The maximum (DMSO control) and minimum values (total cell kill) were fixed. Each IC 50 value was generated from the data of three identically treated cell plates for each of the three independent experiments. Means ± SDs were calculated from three subsequent runs. Statistical analysis (ANOVA/Bonferroni posttest) was performed using GraphPad Prism (GraphPad Software Inc., La Jolla, CA).
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RESULTS
Cell Line Performance With Reference Compounds
To evaluate assay performance, a set of six compounds spanning the IC 50 range from 1 to 300lM was run in triplicate on three consecutive days. Mean and SD are shown in Table 1 . For all compounds, the mean ± 3SD was less than threefold different between the mean À3SD and the mean þ 3SD. Therefore, only IC 50 values with > threefold difference were considered statistically significant.
Cell Line Sensitivities to Compound Treatment
Three cell lines of different target tissue origin, namely, HepG2 (human hepatocellular carcinoma), H9c2 (rat embryonic myocardium), and NRK-52E (human kidney proximal tubule), were utilized to investigate the performance of each cell line toward the detection of general (any type of organ toxicity) cytotoxicity. Cells were exposed to compounds in a dose-response curve for 72 h as described in detail in the ''Materials and Methods'' section, and cell viability was evaluated using an ATP depletion assay. The compound test consisted of 497 compounds, reported to cause hepatotoxicity, cardiotoxicity, nephrotoxicity, or no toxicity in animals and/or humans. This compound set included commercially available compounds as well as Pfizer proprietary compounds. Figure 1 shows that, of the 497 compounds, 13% were detected within a 10lM IC 50 cutoff range using H9c2 cells, 9% using NRK-52E cells, and 10% using HepG2 cells. For the cumulative up to a 25lM IC 50 cutoff range, we detected 24% using H9c2 cells, 17% using NRK-52E cells, and 20% using HepG2 cells. This analysis was continued for IC 50 cutoff IC 50 values were 56% for H9c2, 54% for NRK-52E, and 58% for HepG2 cells. One-way ANOVA (and nonparametric) analysis was performed using the three datasets, and no significant difference was found between the three cell lines for any of the IC 50 cutoff ranges.
Cell Line Specificities to Compound Treatment
Following the cell line sensitivity analysis, we next investigated if the cell lines detected the same compounds or if there were significant differences between them. To address this question, we first looked at each individual compound IC 50 distribution between two cell lines. Figures 2A-C show the scatter plots comparing compound IC 50 values between cell lines. We observed that most compounds were populated along the diagonal line, which indicates that those compounds share similar IC 50 values between paired cell lines. Statistical analysis revealed that indeed no statistical difference was found to exist between any of the cell lines with respect to compounds detected. The correlation coefficients were 0.90 between H9c2 and NRK-52E cells, 0.91 between H9c2 and HepG2 cells, and 0.89 between NRK-52E and HepG2 cells.
However, we did find that 23 compounds displayed IC 50 values that differed by more than threefold from cell line to cell line. The compounds and their respective IC 50 values can be found in Table 2 . For example, axitinib was much more potent in H9c2 and NRK-52E cells than in HepG2 cells, whereas azathioprine was less cytotoxic to H9c2 cells but moreso to NRK-52E and HepG2 cells.
Specificity and Sensitivity Assessment for General Cytotoxicity
The ultimate goal of cytotoxicity screening is to predict compound toxicity in either preclinical species or humans. Toward this end, we compiled 212 commercial compounds with toxicity information available from the literature and 72 compounds with no reported toxicity. Compounds were categorized as toxic or nontoxic as described in detail in the ''Materials and Methods'' section. Compound annotation can be found in Supplementary tables A-D. Our analysis focused on evaluating the relationship between compound in vitro cytotoxicity (IC 50 value) and compound toxicity in human. To do so, we ranked the compounds based on their cytotoxicity (IC 50 ) values from lowest to highest IC 50 value. Next, for each IC 50 value, the sensitivity (defined as the fraction of correctly predicted positives to all true positives in the clinic) and the specificity (defined as the fraction of correctly predicted negatives to all true negatives in the clinic) were calculated (Saah and Hoover, 1997) .
For the predictive organ toxicity analysis, only commercial compounds with literature-reported human C max information were included. No Pfizer internal compounds were included, due to the lack of human C max information. This reduced the compound set to 109 hepatotoxicants, 62 cardiotoxicants, 41 nephrotoxicants, and 72 compounds not known to cause toxicity in humans. All these compounds were commercially available compounds. Figure 3 (black lines) shows that all three cell lines had similar sensitivity and specificity values, and no statistically significant difference was found. Overall, at 80% sensitivity, less than 40% specificity was achieved. Therefore, we expanded our analysis and investigated if consideration of human C max value would change the sensitivity and specificity for the individual cell lines. For this exercise, all cytotoxicity IC 50 values were divided by their compound's C max values (lM), and these values are defined as C max -normalized IC 50 values. Just like before, compounds were ranked based on this normalized IC 50 values, and sensitivity and specificity were calculated. Figure 3 (colored lines) shows that sensitivity and specificity looked different from the values displayed in Figure 3 (black lines). However, again, the differences between the cell lines were not statistically significant. However, the overall predictivity was significantly higher for each of the cell lines when C max was taken into consideration (p < 0.0001). At 80% sensitivity, specificity was 68% with H9c2, 59% with HepG2, and 55% with NRK-52E. Figure 3 demonstrates an increase in sensitivity for each cell line for the C max -normalized IC 50 values, and this difference was found to be statistically significant.
Can We Predict Specific Organ Toxicities?
Thus far, we have shown equal predictivity toward toxicity for each of the cell lines and that C max incorporation increased sensitivity significantly. Here, we extended our focus toward the prediction of a particular organ toxicity. In other words, we wanted to know if HepG2 cells were most suitable for detecting hepatotoxicants, H9c2 cells for detecting cardiotoxicants, and NRK-52E for detecting nephrotoxicants. For the predictive organ toxicity analysis, only commercial compounds with literature-reported human C max information were included. No Pfizer internal compounds were included, due to the lack of human C max information. This reduced the compound set to 109 hepatotoxicants, 62 cardiotoxicants, 41 nephrotoxicants, and 72 compounds not known to cause toxicity in humans. Supplementary tables A-D show the individual compounds sorted into the following categories: hepatotoxicants, cardiotoxicants, nephrotoxicants, and nontoxic compounds with the measured IC 50 values. Compound annotation and C max values were derived as stated in the ''Materials and Methods'' section and were of our best knowledge at this time. This does not imply that compounds could potentially change categories over time as more safety evaluation becomes available. We applied the same approach as above to answer the following questions: 
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LIN AND WILL Does a C max -considered analysis strengthen the organ toxicity prediction? and (3) Does the organ toxicity prediction differ from the previously reported general toxicity prediction?
Does the Use of HepG2 Cells Increase the Predictivity for
Hepatotoxicity? For this analysis, 109 compounds known to cause hepatotoxicity and with reported human C max values and 72 compounds not known to cause toxicity, which also had reported C max values, were utilized. Similar to the results in Figure 3 , the curves were generated for either the IC 50 value only or the C max -normalized IC 50 values (Fig. 4A) . As for the general toxicity prediction, the C max -normalized values improved the predictivity significantly (p < 0.001). Next, we compared the prediction for hepatotoxicity to that of the total (general) cytotoxicity (Fig. 4A) . The IC 50 -based analysis showed no statistically significant difference between the hepatotoxicity prediction and the general toxicity prediction (Fig. 4A, black lines) . The same was true for the C max -based analysis (Fig. 4A, red lines) , which showed an increase in predictivity over non-C max -normalized prediction but no difference between C max -normalized hepatic and general toxicity prediction. Next, the HepG2 C max -based hepatotoxicity prediction was compared with the C max -based hepatotoxicity prediction of the other two cells, namely, NRK-52E and H9c2 (Fig. 4B ). No statistical difference was found between the three cell lines for the prediction of hepatotoxicity. The detailed data can be found in Table 3 . At 90% specificity, HepG2 cells display 45% sensitivity. The positive predictive value (PPV; fraction of toxic compounds correctly predicted) was 0.88, which means that 88% of the time a compound was called out as toxic correctly. The negative predictive value (NPV; fraction of nontoxic compounds correctly predicted as nontoxic) was 0.52, which means that 52% of the time a negative compound will be truly negative. However, 48% of the time, the compound could still be toxic (FNR, false-negative rate; percentage of toxic compounds not correctly predicted). The false-positive rate (FPR; percentage of nontoxic compounds predicted to be toxic) for this category was 13%. The C max cutoff value was 34lM, which means that in order to achieve a 90% specificity no compounds with C max value > 34 could be considered. Values are also reported for 95 sand 100% specificity. H9c2 cells and NRK-52E cells performed very similar to HepG2 cells (Table 3) . At a specificity of 90%, H9c2 cells had a PPV of 0.87 and NRK-52E of 0.86. The FPR were 3. Specificity and sensitivity assessment for general cytotoxicity. HepG2 (d), H9c2 (:), and NRK-52E (¤). Black lines represent the IC 50 -based toxicity prediction, whereas the colored lines present the C max -normalized IC 50 toxicity prediction. Sensitivity (X) was calculated as percentage of total toxicants detected within a specific IC 50 or C max -normalized IC 50 range (toxicants detected divided by total toxicants). Specificity (Y) was calculated as percentage of total nontoxicants that were not detected within a specific IC 50 or C max -normalized IC 50 ranges (nontoxicants without being detected divided by total nontoxicants).
IN VITRO PREDICTION OF ORGAN TOXICITY was also similar to that of HepG2 cells. It was 0.51 and 0.49 for H9c2 and NRK-52E, respectively. The C max cutoff values are 33 and 31lM for H9c2 and NRK-52E, respectively. All three cell lines showed a rather large FNR (48-51%) at a FPR below 14%. In other words, many compounds, which were toxic to humans, remained undetected in any of the cell lines (Table 3) .
Does the Use of H9c2 Cells Improve the Predictivity for
Cardiotoxicity?
For this analysis, 62 compounds known to cause cardiotoxicity and with reported human C max values and 72 compounds not known to cause toxicity, which also had reported C max values, were utilized in the prediction analysis. The analysis was carried out in the same way as for the hepatotoxicants. Figure 4A for hepatotoxicants, the curves were generated for either the IC 50 value only or the C max -normalized IC 50 values (Fig. 4C) . C max normalization significantly improved the overall predictivity for cardiotoxicity (p < 0.004). Next, we compared the prediction for cardiotoxicity to that of the total (general) cytotoxicity prediction (Fig. 4C) . The IC 50 -based analysis (black lines) showed no statistically significant difference between the cardiotoxicity prediction and the general toxicity prediction (Fig. 4C) . The same was true for the C max 3 based analysis (red lines), which showed an increase in predictivity over non-C max -normalized prediction but no difference between C max -normalized cardiac or general toxicity prediction. Next, the C max -based H9c2 cardiotoxicity prediction was compared with the C max -based cardiotoxicity prediction of the other two cells, namely, NRK-52E and HepG2. Figure 4D illustrates the data. No statistical difference was found between the three cell lines for the prediction of cardiotoxicity. The detailed data are found in Table 3 . At 90% specificity, H9c2 cells display 43.5% sensitivity. The PPV was 0.79 (79%). The NPV was 0.66. The FPR for this category was 21%. The C max cutoff value was 33lM. Values are also reported for 95 and 100% specificity. HepG2 cells and NRK-52E cells were very similar to the H9c2 cells (Table 3) . At a specificity of 90%, HepG2 cells had a PPV of 0.77 and NRK-52E of 0.75. The FPR was 23 and 25% for HepG2 and NRK-52E, respectively. The NPV was also similar to that of H9c2 cells. It was 0.64 and 0.63 for HepG2 and NRK-52E, respectively. All three cell lines have a rather large FNR (34-38%). The C max cutoff value for H9c2 cells was 33lM, very similar to HepG2 (34lM) cells and for NRK-52E cells, 31lM.
Does the Use of NRK-52E Cells Improve the Predictivity for
Nephrotoxicity?
For this analysis, 41 compounds known to cause nephrotoxicity and with reported human C max values and 72 compounds not known to cause toxicity, which also had reported C max values, were utilized in the prediction analysis. The analysis was carried out in the same way as for the hepatotoxicants and cardiotoxicants. Similar to the results shown in Figures 4A and  4C for the hepatotoxicants and cardiotoxicants, the curves were generated for either the IC 50 value only or the C max -normalized IC 50 values (Fig. 4E) . Unlike in Figures 4A and 4C , the predictivity toward nephrotoxicity (black lines) was much lower than the predictivity toward general toxicity. However, when 
Notes. The analysis was carried out based on the C max -normalized IC 50 values. At 100% specificity, the IC 50 /C max ratio was < 2. All compounds with an IC 50 / C max ratio < 2 were considered assay positive, whereas all others were considered assay negatives. Sensitivity was calculated by dividing the number of correctly identified toxicants (TP) by the number of total toxicants (TT) in the test set. Specificity was calculated by dividing the number of correctly identified nontoxicants (TN) by the number of total TN in the test set. The PPV is defined as the ability to correctly identify toxicants, and the NPV is defined as the ability to identify nontoxic compounds as truly negative. The FPR was calculated as 1 À PPV and the FNR as 1 À NPV.
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normalized to C max (red lines), the predictivity now was very similar to the one for general toxicity.
The detailed data are found in Table 3 . At a 90% specificity, NRK-52E cells display 58% sensitivity. The PPV was 0.77 and the NPV was 0.79. The FPR for this category was 23% and the FNR was 21%. Values are also reported for 95 sand 100% specificity. HepG2 cells and H9c2 cells were very similar to the NRK-52E cells (Table 3) . At a specificity of 90%, H9c2 cells had a PPV of 0.78 and HepG2 cells of 0.77. The FPR was 22 and 23% for H9c2 and HepG2, respectively. The NPV was also similar to that of HepG2 cells. It was 0.79 and 0.80 for HepG2 and H9c2, respectively. The C max cutoff value was very similar between all three cell lines. It was 31, 33, and 34lM for NRK-52E, H9c2, and HepG2 cells, respectively.
Does the Application of Multiple of C max Projection Improve
Predictivity Toward a Particular Organ Toxicity? Xu et al. (2008) showed that for hepatotoxicity, predictivity improved if the safety margin was calculated using a 1003 C max . Here, we explored how the predictivity would change if we calculated the safety margin over the 13, 303, and 1003 C max values. Table 4 shows the results. Indeed, the analysis indicates that 1003 C max increases the sensitivity for hepatotoxicants significantly. Whereas the sensitivity at 13 C max was 4.6%, it increased to 39.4% at 303 C max and increased to 67.9% at the 1003 C max . This increase in sensitivity, however, was achieved at the cost of losing specificity. Whereas the specificity at 13 C max was 100%, it decreased to 90.3% at 303 C max and further decreased to 75% at the 1003 C max . The same was also observed for the cardiotoxicity and nephrotoxicity prediction (Table 4) . In both cases, sensitivity increased significantly from 13 C max to 303 C max and further at 1003 C max , but the specificity was reduced by close to 20%. In order to achieve relatively good specificity (90%), our data imply that 303 C max is the best cutoff for the prediction of hepatotoxicants, cardiotoxicants, and nephrotoxicants (Table 4) .
DISCUSSION
Late-stage drug attrition of drugs accounts for a substantial amount of total development costs. Consequently, there is a strong need to improve predictive toxicology through the development and deployment of assays that accurately forecast toxicity of compounds as early as possible in the drug development process.
Hepatic and cardiac toxicity have been the main reasons for late-stage drug attrition. Those, as well as nephrotoxicity, remain Pfizer's own preclinical and clinical toxicity problems. In recent years, efforts have been made to identify such liabilities earlier in the drug development process, through utilization of in silico and in vitro toxicity models. For example, pharmaceutical companies for many years have routinely utilized the Ames mutagenicity assay to assess carcinogenic potential of new chemical entities (NCEs). Recently, several assays have been developed and applied to predict possible cardiovascular toxicity in humans, such as QT prolongation, which have been linked to torsade de pointes (Antzelevitch, 2007; Bauman et al., 1984) .
Although in vitro assays have been utilized for many years, the data have not been applied consistently to the decision making process in early drug development because in vitro toxicity data have not proven to be a reliable predictor of in vivo toxicity in either animals or humans (McKim, 2010) . Recently, Benbow et al. (2010) reported that safety findings in rodent in vivo studies could be approximated using cytotoxicity values. Greene et al. (2010) expanded on these observations, by demonstrating that compounds with IC 50 values < 50lM were five times more likely to give rise to one or more adverse finding at C max < 10lM in a rodent in vivo study.
Here, we took a stepwise approach to understand assay performance of each of the three cell lines, their ability to predict general organ toxicity, as well as a particular organ toxicity, such as cardiac, hepatic, or nephrotoxicity.
The ATP assay was used throughout our studies as a surrogate for cell viability. The assay is HTS compatible, has excellent reproducibility and sensitivity, and is free from fluorescent interference. However, the assay cannot differentiate Notes. At a 303 C max cutoff, all compounds were defined as assay positives if the 303 C max value exceeded their IC 50 values and as assay negative if the C max value was lower than their IC 50 values. Sensitivity, specificity, PPV, NPV, FPR, and NPR were calculated in the same way as in Table 3 . TI ¼ therapeutic index.
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LIN AND WILL between cytotoxic and cytostatic compounds (Kangas et al., 1984; Petty et al., 1995) . Other assays such as 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) or lactate dehydrogenase (LDH) release could potentially also be used and should yield similar results (Miret et al., 2006; Mueller et al., 2004) . Our assay validation demonstrated consistent means and low SDs over three consecutive days of testing. From these data, we established that only compounds with IC 50 values more than threefold difference could be considered significantly different.
Next, we engaged in a large-scale evaluation of compounds that were hepatotoxic, cardiotoxic, or nephrotoxic or had no reported organ toxicity. We screened these compounds in all three organ-specific cell lines. We found that the cell lines exhibited a similar sensitivity to the entire set of compounds. In fact, only 23 compounds differed in their IC 50 value by more than threefold between the three cell lines. Interestingly, the higher sensitivity found in a particular cell line for any of these 23 compounds was not always indicative of its proposed primary organ toxicity. For example, clarithromycin, known to have cardiac liabilities, was much more potent in H9c2 cells (17.9lM) than in HepG2 (85.3lM) and NRK-52E cells (101.2lM), whereas floxuridine, a potent hepatotoxicant, gave no response in HepG2 cells (300lM) but was very potent in NRK-52E cells (1.8lM).
Our work compares to Xia et al. (2008) who tested 1408 compounds in 13 human and rodent cell lines. Cells were either transformed or primary. The authors report that some compounds were cytotoxic to all cells at similar concentrations, whereas others exhibited species-or cell type-specific cytotoxicity. The authors concluded that this approach might be valuable for prioritizing compounds for further toxicology evaluation and to identify compounds with a particular mechanism and/or action. In our study using 497 commercial and Pfizer proprietary compounds, we observed the same phenomenon: cell response was compound specific but only in rare cases cell type dependent. Our study is also in concert with a study conducted by Schoonen et al. (2005) who tested 100 compounds in HepG2 cells and HeLa cells and 60 compounds in ECC-1 and CHO cells. The authors concluded that in general, all tested compounds gave similar dose and toxicity profiles in all cell lines. Only three compounds differed.
Next, we expanded our studies by testing for each cell line for its ability to detect a particular organ toxicity. We had hypothesized that HepG2 cells would be superior in detecting hepatotoxicants, whereas H9c2 and NRK-52E would be superior for cardiac and nephrotoxicants, respectively. This was not the case. All cell lines were equally suitable for detecting any of the organ toxicities, which is in accord with our first study that showed equal predictivity to all toxicants. So how does our study differ from others that aimed to predict a specific organ toxicity? It is commonly believed that in order to predict specific organ toxicity, one must measure a suitable endpoint in an organ-specific cell line. For example, hepatotoxicity is generally investigated using rat or human hepatocytes (Schutte et al., 2011) , whereas cardiotoxicity is assessed using rat embryonic cardiomyocytes (Fu et al., 2010) . The endpoints utilized for toxicity evaluation range from the cytotoxic endpoints, such as LDH, MTT, and ATP, often run in plate-based application, to more sophisticated mechanistic endpoints, such as reduced glutathione (GSH) content, reactive oxygen species formation, mitochondrial function, apoptosis, endoplasmatic reticulum stress, and DNA damage utilizing newer and more sophisticated imaging applications, such as high-content imaging or flow cytometry.
These endpoints, however, can potentially contribute to a variety, if not the majority, of organ toxicities. For example, it has been well established that GSH depletion can lead to hepatotoxicity as well as to nephro-and cardiotoxicity (El-Shitany et al., 2008; Fu et al., 2010; Li et al., 2011) . Mitochondrial dysfunction and apoptosis have been implicated in hepatotoxicity, nephrotoxicity, and cardiotoxicity .
All cells have the basic machinery for cell survival and replication (if immortalized) and cell injury pathways that can be activated after xenobiotic insult. Therefore, we wanted to understand how much impact the choice of cell line would truly have in predicting the organ toxicity outcome. Searching the literature, we also found that when researchers examined a particular organ toxicity, they rarely included compounds that caused different organ toxicity than the one of interest. In other words, nobody studies the cardiotoxic effects of doxorubicin using rat hepatocytes. For example, O'Brien et al. (2006) and Xu et al. (2008) have conducted large-scale in vitro evaluations of hepatotoxic compounds with the aim of predicting druginduced liver injury in vivo. The first study, O'Brien et al. (2006) , used HepG2 (human hepatoma) cells and a high-content imaging approach. HepG2 cells are a simple, readily accessible, and almost unlimited source of cells from a human liver. However, a major limitation is their reduced drug-metabolizing capability in comparison to primary hepatocytes, which can contribute to the differences in cytotoxicity found in both cellular models (Westerink and Schoonen, 2007a,b) . O'Brien et al. (2006) tested 243 drugs and chemicals, which were grouped as follows: (1) severely hepatotoxic drugs, (2) moderately hepatotoxic drugs, (3) nontoxic drugs, and (4) drugs toxic to other organs. In addition, a variety of toxic and nontoxic chemicals were also tested. Cells were incubated for 72 h with the highest drug concentrations being 303 C max (maximum achieved plasma concentration of a particular drug) or 100lM (if C max was not available) in a dose-response curve. IC 50 values were generated for cell number, nuclear area, calcium content, and mitochondrial membrane potential. The sensitivity for this assay was reported to be 85% with a specificity of 98%. However, compounds known to cause other organ toxicities were included in the testing, but not in the prediction for hepatotoxicity.
The second large-scale study was conducted by Xu et al. (2008) . This study tested over 300 drugs and chemicals, many of which caused liver injury in humans. The study utilized primary human hepatocytes maintained in a matrigel-overlayed culture. Hepatocytes were treated with each drug at a concentration equal to 1003 C max (reported for humans) on day 3 and subjected to high-content imaging of intracellular glutathione, mitochondrial damage, and oxidative stress after 24 h. A compound was considered true positive if any of the endpoints (or multiple endpoints) were positive at the 1003 C max testing concentration. The assay had a true positive rate between 50 and 60% at the testing dose of 1003 C max and a FPR of 0-5%. How did Xu derive the scaling factor of 100? For Xu to identify an idiosyncratic hepatotoxic drug with a serious hepatotoxic event happening in less than 1 in 1000 patients, he needed to predict a population's outlier response rather than its mean response. Xu used a scaling factor of sixfold to account for population C max variability from the average therapeutic C max that was collated from the literature to account for patient genetic (such as metabolic enzymes and transporters) and epigenetic factors (such as age and preexisting disease), which affect drug clearances. Additionally, a sixfold uncertainty factor was used to account for higher drug exposure to the liver via liver portal vein for an orally dosed drug and a final threefold uncertainty factor to account for drug-drug or drug-diet interactions due to increased usage of polypharmacy and naturaceuticals, and potential for increased drug exposure upon multiple days of dosing compared with the single-dose C max values, resulting in a combined 100-fold of the C max values (Xu et al., 2008) . Our study shows that the prediction of hepatotoxicity at 303 C max was given as a slightly lower sensitivity than Xu observed, but a much higher specificity. This difference might be due to the fact that Xu also tested compounds at much higher concentrations than 300lM. Our results are more in concert with O'Brien et al. (2006) , who also found that 303 C max resulted in the best prediction. However, again, compounds known to cause other organ toxicities were included into the testing, but not into the prediction for hepatotoxicity.
In contrast, much smaller compound sets have been evaluated for cardiac and nephrotoxicity (Inoue et al., 2007; Wu et al., 2009; Zhang et al., 2007) . Zhang et al. (2007) evaluated three hepatotoxicants and three nephrotoxicants in the human hepatoma cell line Bel-7402 and the human renal tubular epithelial cell line HK-2. The authors measured cell viability, mitochondrial membrane potential, and the neutral red assay. The authors found good correlation for 2/3 hepatotoxicants and 1/3 nephrotoxicants when using the neutral red assay. Metabolic activation by S9 increased the toxicity for 2/6 compounds. The authors conclude that in vitro assays could potentially predict organ toxicity, but if no correlate existed to the observed organ toxicity, then absorption, distribution, metabolism, and excretion properties most likely would have to be considered. Inoue et al. (2007) used neonatal rat heart cells and adult rat hepatocytes to predict cardio-and hepatotoxicity. They tested four anthracyclines and five hepatotoxicants in their system. All anthracyclines displayed an IC 50 value < 2lM at 24 h in the neonatal cardiac cells, whereas the IC 50 values in the rat hepatocytes were between 10 and 20lM. Of the five hepatotoxicants, one compound, namely, acetaminophen, was more toxic in the rat neonatal cells than in the rat hepatocytes. For the other four compounds, IC 50 values were less than twofold different in the two cell lines. The authors suggest that taking the ratio of one cell line over the other would be predictive of possible organ toxicity. Given the less than twofold difference for the hepatotoxicants, this approach might not be valid with a larger compound set and certainly was not the case with our large compound set with the exception of the said 23 compounds.
To our surprise, the prediction of cardiotoxicity and nephrotoxicity was also increased at 303 C max . Our findings are supported by a recent expert opinion review by Weiss (2011) who examined drug uptake and metabolism in the heart. He reports a heart-to-plasma concentration of 20 for idarubicin and 40 for doxorubicin 24 h after injection into rabbits. Minocycline, which is an antibiotic with cardioprotective effects, was shown to accumulate in rat hearts by 24-fold. In addition, Nagai (2006) reported a selective accumulation of aminoglycosides in the renal cortex, causing toxicity. The same is true for cephaloridine (Koren, 1989) .
Our study expands on that observation by testing for possible organ toxicity in organ-specific cell lines and including C max projection. Our results suggest that the compound-induced cytotoxicity is of a more general nature and the mechanisms are present in all cell lines. Based on our data, any of these three cell lines (possibly others as well) could be used as a first pass to examine possible cytotoxicity. However, a prediction toward organ toxicity cannot be made using this simple approach. The toxicity of compounds used in humans especially via oral application is much more complicated and dependent not only on the compound dose ingested but also on the compound metabolism. Therefore, compound PK information is essentially important in compound efficacy and toxicity and will affect in vitro toxicity prediction. Unfortunately, PK information is not available at the early stage of compound development. Therefore, retrospective study on market compounds using in vitro cytotoxicity assays becomes meaningful to reveal compound safety space between in vitro toxic concentration and human toxic dose as well as compound C max values. Our study showed at an accuracy of 90% the toxic compound prediction can reach up to 50% when C max data (303 C max cutoff) can be considered in contrast to only 20% in the absence of such information. In the absence of projected efficacious drug concentration or available C max data, the data can at most be used to rank-order compounds. However, that assumes that the efficacy is equal. If binding assay Ki values or cell-based assay data are available, one can potentially compare the cytotoxicity IC 50 data as a ratio to those values. Unfortunately, the prediction of C eff or C max is much more difficult in the preclinical arena. For example, the antidepressants nefazodone and trazodone have been associated with liver toxicity, whereas no toxicity has been reported for buspirone (DeSanty and Amabile, 2007) . In fact, nefazodone has been withdrawn from most markets. At first glance, it appears that both trazodone (IC 50 ¼ 220.3lM) and buspirone (IC 50 ¼ 253lM), are fairly nontoxic in the ATP depletion assay, whereas nefazodone (IC 50 ¼ 24.7) was much more toxic. However, inclusion of C max shows that trazodone only has a marginal better safety margin (IC 50 /C max ) than nefazodone (43.6 vs. 26.7, respectively), in contrast to buspirone, which has a very high safety margin (19, 523) .
Another example is the thiazolidinones troglitazone, pioglitazone, and rosiglitazone. Troglitazone was withdrawn from the market due to idiosyncratic hepatotoxicity. Rosiglitazone and pioglitazone carry a black box warning for cardiotoxicity as a possible class effect, and recently, rosiglitazone was withdrawn due to increased cardiac liabilities. The ATP depletion assay revealed that all three compounds were fairly nontoxic (IC 50 > 100lM). However, C max inclusion reduced the safety margin for troglitazone to 20 in contrast to pioglitazone and rosiglitazone, where the safety margin was > 200 for pioglitazone but only 8 for rosiglitazone, which as mentioned was recently withdrawn.
Our dataset included a variety of statins such as simvastatin, atorvastatin, fluvastatin, and lovastatin. All statins have been associated with some form of mild to moderate muscle toxicity and in rare cases hepatotoxicity. All statins were rather potent in the ATP depletion assay (IC 50 < 30lM). However, C max -based calculation gave very different safety margins for the statins. Whereas lovastatin and simvastatin achieved a high safety index due to their low C max values, atorvastatin and fluvastatin had a much lower safety margin. This might be due to their selected uptake by The monocarboxylate transporter (MCT4) transporter. One could speculate that fluvastatin and atorvastatin are much more potent substrates for MCT4 than, e.g., lovastatin or fluvastatin. No reports in the literature have examined this to date.
We also examined two anthracyclines. Whereas doxorubicin has been associated with cardiotoxicity, reports on daunorubicin are more frequent. Whereas the C max -based safety margin is 0 for doxorubicin, the safety margin for daunorubicin is 10-fold higher.
It appears that the safety margin might be adjusted to the therapeutic area. For example, an oncology drug might advance with a much lower safety margin than an antidiabetic drug, which will be administered for an extended period of time. Retrospective analysis of commercial drugs, and more importantly, the commercial drugs and attrited compounds developed by the pharmaceutical industry, should provide guidance toward establishing safety margins. In addition, the accurate prediction of human C eff is of paramount importance, but often not achieved until in the clinic.
The above examples demonstrate the value of C maxconsidered toxicity prediction. However, the experimental design needs to be taken into some consideration. For example, when applying 303 C max prediction, test compounds with C max values 10lM have to be tested at 300lM to be considered negative. Compounds that exceed 10lM C max values cannot be accurately predicted to be negative. The ideal test compound concentration would be at the 303 C max concentration, although it is not pragmatic in many cases. As to the nontoxic control compound selection, the C max value of those compounds is of paramount importance. Our experience shows that in the 303 C max prediction analysis, compounds with C max value < 3lM serve better as negative controls in the data analysis. Compounds with C max values > 10lM automatically become false positive because their 303 C max exceeds the maximum test concentration.
In summary, we have shown that a variety of cell lines can be used for assessment of cytotoxicity of NCEs. In rare occasions, differences can be encountered which can be due to metabolism or transporter differences. There is a strong need for improvement of the large percentage of remaining falsenegative compounds. Here, we made the assumption that organ toxicity is a result of cytotoxic response. Many cardiotoxicities could be ion channel related and would remain undetected for the most part. For example, the hERG (the human Ether-à-go-go Related Gene) channel is not expressed in the majority of cell lines. Liver toxicity can be due to reactive metabolite formation as well as inhibition of the bile salt efflux transporter. We neither used metabolically competent cells nor do we have bile salt efflux pump (BSEP) expression in our cell systems. In addition, liver toxicity due to allergic reactions cannot be modeled here as it would require coculture with a variety of cell types that can mount an immune response. In addition, some drugs might need extended exposure beyond 72 h. Some nephrotoxicants require megalin expression to exhibit toxicity, such as tobramycin, amikacin, carboplatin, cisplatin, gentamycin, and netilmicin. Newer approaches, such as coculture models, high-content screening of mechanistic endpoints, reporter assays, and zebrafish might be able to further improve the false-negative space. The availability of the projected efficacious drug concentration or C max is essential to truly rank-order compounds, as we have shown using selected examples.
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